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ABSTRACT 
Zhang, Lucy Chen, Master of Public Policy, Johnson-Shoyama Graduate School of 
Public Policy, University of Saskatchewan, Canada, 2013.  
 
Policy Evaluation: A Case Study of Genome Canada Programming, 2000-2011. 
Supervisor: Dr. Peter W. B. Phillips 
The policy evaluation literature on research programing generally focuses on the 
cost-benefit of different choices in research systems. This thesis applies evaluation tools 
to assess the fit between project allocations and the strategic goals of Genome Canada, a 
major research funding organization in Canada.  
Genome Canada (GC) was established in April, 2000, to provide funding and 
information resources related to genomics research. The research targets many key areas, 
such as health, agriculture, environment, forestry, energy, mining and fisheries.  
Since then the scientific community has partnered with government, the private 
sector, and international organizations to fund research projects on genomics related 
subjects. Four open competitions (I, II, III and Applied Genomics in Bio-products and 
Crops or ABC), combined with a wide array of  more targeted projects, have collectively 
been allocated more than C$2 billion in total investment for the 2000-2014 period.  
This study assesses how well these research projects fit the stated goals of Genome 
Canada. The study assesses the fit between the goals and research investment decisions of 
GC. As a first step in this research, we conducted a review of Genome Canada operations 
to develop the background understanding of the system and its structure. After reviewing 
the goals, structure, selection processes and progress reports, we found that there was no 
explicit assessment of the fit between the stated goals and resource allocation decisions. 
This study targets to fill this area. 
Second, we investigated the methods used by GC to develop and implement their 
goals. Once we understood these methods, we developed a research approach to assess 
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the fit between the goals and the outputs. The model was built to test each project against 
the stated overall program objectives, namely to: develop and implement a coordinated 
strategy for the technology in Canada; bring together industry, governments, universities, 
research hospitals and the public to support large-scale genomics and proteomics research 
projects; provide accessibility to science & technology platforms to researchers; and 
assist in attracting co-funding for projects from both domestic and international investors.  
Third, we determined that the review processes contain scientific, financial and 
management criteria. By using the STATA tool, we tested the relationship between the 
stated goals of the organization and the share of funds allocated to specific projects both 
in the total pool of investments and the open competitions.  
 The analysis revealed that the overall fit for the entire investment program between 
2001 and 2011 was about 35%, which is quite reasonable for such an analysis. We found 
the most important variable affecting resource allocation was the quality of the principal 
investigator. Other stated goals of GC were either less important or insignificant. By 
segmenting the analysis into the open-competition investments alone, we discovered the 
fit deteriorated (R
2
 of 34% dropped to 22%), which suggests the directed investments are 
a stronger fit with the goals. While we could not conclusively determine the cause, it 
might be attributed to either weaknesses in the competitive process or a particularly 
effective and strategic effort by Genome Canada staff. Further analysis would be needed 
to determine this. 
 
KEY WORDS: evaluation; research management; Genome Canada; program assessment.  
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1. Introduction 
1.1. Genome Canada Overview 
Genome Canada (GC) was established in April, 2000. It is an example of an independent 
non-profit organization, that provides funding, coordination and information resources 
related to research, in its case for genomics and proteomics research in Canada. The 
research targets the development and implementation of strategies and large scale 
research projects in key bio-science areas (i.e., health, agriculture, environment, forestry, 
fisheries, mining and energy) in order to help Canada become a world leader in genomics 
and proteomics research.  
Genome Canada is based on the premise that the funding and management of large-scale  
interdisciplinary and internationally peer-reviewed research projects along with S&T 
(science and technology) Innovation Centers  can effectively translate research results 
into broader commercial outcomes. Genome Canada operates in close collaboration with 
its primary partners—the six Genome Centers, located in British Columbia, Alberta, the 
Prairies, Ontario, Quebec, and the Atlantic region. The relationship established between 
Genome Canada and each of the Genome Centers is defined by means of a funding 
agreement that “not only acknowledges the independence of each Genome Centre, but 
also specifies the parameters in which each Centre is to operate and contribute to Genome 
Canada’s overall mandate”.1 
Over the past decade, Genome Canada has established Canada as a recognized world 
leader in the promotion of research on the ethical, environmental, economic, legal and 
social (GE3LS) aspects of genomics research. While GC has undergone the usual 
organizational, administrative and financial reviews, it has not undertaken any specific 
evaluation of the process of targeting its operating model to realize its stated goals. This 
thesis addresses that gap. 
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1.2. Problem statement 
A critical part of any effective public policy assessment is to compare activities and 
outputs against the authorized goals and objectives of the initiative. In most cases, the 
outputs are assumed to conform to the stated goals and objectives but are not assessed as 
part of a formal evaluation. 
This project explicitly assesses the choices made by Genome Canada in the context of its 
funding competitions to determine how the organizational goals are reflected in the 
projects selected.  
1.3. Approach 
Genome Canada has developed a detailed operational style. While the order of the early 
steps in each competition might vary, all of the competitions followed a common path.  
First, after consultation with industry, government, the scientific community and end 
users, (sometimes informally and sometimes through the use of formally structured theme 
papers), GC would frame a funding request for Industry Canada that states what area the 
organization would focus on and what the money would be used for. If successful, GC 
would then devise competition objectives. Most federal requests were only partially 
awarded.   
Second, GC would issue a call for proposals, which would articulate the focus and scale 
of projects that could be funded. In most cases letters of intent are first reviewed and in a 
few cases were used to triage the proposals. Projects would be evaluated and invited to 
submit full proposals. Full proposals for the open competitions would be peer-reviewed 
and assessed by panels of international reviewers. The Genome Canada Board would 
then approve the allocations. Each approved project embodied milestones which would 
trigger quarterly progress reports and a final statement of activities and outputs.  
In the context of this effort, Genome Canada regularly undertakes financial reporting that 
is audited, has engaged in organization and process evaluations and has assessed the 
outputs of the competitions. To date, the organization has not obviously assessed the 
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efficacy and appropriateness of the funding allocation decisions themselves and their fit 
to the organization’s mandate and objectives.  
1.4. Structure 
Our study is designed to assess how well Genome Canada's funding allocations fit the 
organization’s stated goals. This work is structured into five further chapters. Chapter 2 
offers an overview of past GC reports and budgets to provide a background to the 
funding issues and models. Chapter 3 reviews the literature and theory of evaluation 
relevant to this work. Chapter 4 lays out the research method we use to examine the fit 
between the goals and the funding allocation decisions. Chapter five presents the results 
of our analysis. Chapter six examines the policy implications of this study. 
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2. Background 
Genome Canada is a not-for-profit non-government-controlled organization set up by the 
federal government to invest in genomics research in key sectors and foster networks of 
expertise in Canada with a view to generating economic and social benefits for Canadians. 
Over the past decade, Genome Canada has established Canada as a recognized world 
leader in genomics research. The unique approach Genome Canada has adopted ensures 
GE
3
LS (the ethical, environmental, economic, legal and social) aspects are considered 
and integrated into science-based genomics research and large-scale research projects. 
This is posited to have helped enable responsible and beneficial applications of genomics 
science. 
2.1. Objectives of Genome Canada 
Genome Canada identified five key objectives to help move Canada onto the world stage 
in its 2007 corporate strategic plan.
2
 Specifically, the organized seeks to: 
1) Develop and implement a coordinated strategy for genomics and proteomics research 
to enable Canada to be among the world leaders. 
2) Support large-scale genomics and proteomics research projects of strategic 
importance to Canada, which are beyond current capacities, by bringing together 
industry, governments, universities, research hospitals and the public.  
3) Provide accessibility to Science & Technology Platforms to researchers in all 
genomics and proteomics related areas through six regional Genome Centers across 
Canada (Atlantic, Québec, Ontario, Prairie, Alberta and British Columbia). The 
relationship established between Genome Canada and each of the Genome Centers is 
defined by means of a funding agreement that not only acknowledges the 
independence of each Genome Centre, but also specifies the parameters in which 
each Centre is to operate and contribute to Genome Canada’s overall mandate.  
4) Encourage investment by others in the fields of genomics and proteomics, attracting 
co-funding for projects from both domestic and international investors. 
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5) Sustain leadership in research areas on Ethical, Environmental, Economic, Legal and 
Social issues related to genomics and proteomics research (GE
3
LS), and promote the 
communication of the relative risks, rewards and successes of genomics and 
proteomics research to the Canadian public. 
2.2. Genome Canada Governance System 
  
Genome Canada operates within a governance framework that is reflective of its not-for profit 
corporation status. It is governed by a Board of Directors comprising up to 16 individuals drawn 
from the academic, private and public sectors. These individuals bring unique skills and 
experiences as well as strong interests and insights to successfully fulfill Genome Canada’s 
mandate. 
 
Figure 2.1 Genome Canada Structure 
Source: Performance, Audit and Evaluation Strategy 2012-2017
3
 
2.3. Funding & Investments 
As can be seen in table 2.2, as of 2012 Genome Canada had committed $915 million in 
funding and researchers had secured approximately an additional $1085 million in co-
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funding, representing a total investment of over $2 billion in completed or planned 
genomics research in Canada. 
All these investments have laid a foundation for a rich, vibrant genomics research 
community in Canada, and as noted below, have transformed the quantity, scope, scale 
and quality of such research. 
4
 
Table 2.2 Operating Budgets 
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Source: Genome Canada, Genome Canada Corporate plan 2011-2012, Ottawa, 2012.
5
  
Figure 2.2 shows the inflow of funds from the federal government and the range of 
programs and projects funded over the first decade or so of the company's operations. 
 
Figure 2.2 The flow of funds and investments 
Source: Genome Canada, Genome Canada Corporate plan 2011-2012, Ottawa, 2012.
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From the data above and various financial reports, the overall efforts of GC can be 
summarized by the following:
6
 
 $2 billion was invested, with more than half secured from partners; 
 156 large scale research projects across the life science sectors (see appendix 4 for 
the list of projects and their key operating dimensions); 
 five world-class S&T Innovation Centres; 
 more than 200 project leaders, who have developed the skills to manage complex 
science knowledge into application;  
 more than 4,500 research publications; Canada ranks fifth in the world in terms of 
scientific impact, and fourth in the world in research related to science and society; 
 more than 20 companies created;  
 more than 10,000 highly skilled people employed; and  
 8 
 
 more than 350 patent applicants and patent awards, and 24 license agreements; 
Canada ranked first in the multi-criteria ranking for intellectual property in genomics 
in 2005–2007. 
2.4. Selection Process 
As shown in table 2.4, Genome Canada has engaged in four large-scale, open research 
competitions, commonly named competitions I, II, III and the Applied Genomics in Bio-
products and Crops (ABC) competition. The rest of the funding allocations were to 
directed projects/programs (called ‘other’ in this study) that were more directly managed 
and coordinated by Genome Canada or the centres.   
Table 2.4 The large-scale open competitions 
 Start Date Total approved 
budgets 
Number approved 
projects 
Competition I April 4, 2001 $136 million 17 
Competition II July 19, 2001 $155.5 million 33 
Competition III July, 2004 $346 million 33 
ABC April, 2008 $112 million 12 
Total  $749.5 million 95 
Source: Calculation from Genome Canada Corporate plan 2011-2012, Ottawa, 2012.
5
 
Competition I was announced on April 4, 2001. An investment of $136 million was 
allocated in support of 17 large-scale research projects and five science and technology 
platforms across the country.
7
 
On July 19, 2001, Competition II provided funding for several large-scale genomics 
research projects and their related science and technology platforms. A total budget of 
$155.5 million was made available to the 33 selected projects in April 2002.
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Genome Canada introduced Competition III in July 2004 and reported on August 25, 
2005 that $346 million was invested in 33 large-scale projects for the duration of 3 to 4 
years.
7
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Before the end of Competition III, Genome Canada engaged in a strategic research theme 
development exercise, involving  a call for position papers from groups of scientists. In 
April 2008
7
, GC announced a competition focused on applied genomics research in two 
related themes: 1) bio-products; 2) crops, hereafter called the Applied Bioproducts and 
Crops (ABC) competition.  Projects in the bio-products theme were designed to “employ 
genomic and proteomic approaches to understand and manipulate the underlying 
biological processes exploited in the production of economically viable and 
environmentally sustainable bio-products. Three areas were targeted: feedstock 
optimization; microorganisms for sustainable processing technologies; and value added 
bio-products.
 
Projects in the crops theme were required to foster an improved 
understanding of systems that govern plant growth, development and performance. 
Funded projects cultivated a comprehensive understanding of the genetic and 
physiological factors that contribute to the underlying biological processes of Canadian 
crops.” Three areas were targeted: basic plant genomics; applications of plant genomics; 
and agriculture and food production sustainability.
 
Results of this competition were 
announced on April 20, 2009: $112 million was invested in 12 new research projects.
9
 
As discussed above, the selection process involves letters of intent which are vetted and 
approved for full application. This is then followed by submission of full proposals which 
are evaluated through peer review. The performance data in table 2.5 suggests the 
systems have operated somewhat differently in the different competitions. Competition I 
generated the most initial interest but as is common with a new grant program, many of 
the proposed ideas were not appropriate to the mandate of Genome Canada; in the end, 
the agency culled almost three-quarters of the ideas at the LOI stage. Other competitions 
only selectively culled at this stage. A second point of departure is in the submission of a 
proposal—many project leaders withdraw and do not submit a formal funding application 
due to the time and resource commitment of developing the full application. Once a 
project gets to peer review, its likelihood of receiving funding is quite high—ranging 
from 35% to 55% (and likely also if matching funding is easily arranged). Overall, 517 
ideas were identified in LOIs (or registrations), leading to 213 proposals, 45% of which 
were accepted and funded, leading to an overall 18% conversion rate of ideas (at the LOI 
stage) into funded research. 
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Table 2.5 The flow of proposals in the open competitions 
 Competition I Competition II Competition III ABC 
Competition 
Totals 
Letters of Intent 
/Registrations 
275 67 117 58 517 
Full Proposals 
invited 
73 64 93 48 278 
Full proposals 
submitted for peer 
review 
31 62 93 27 213 
Approved projects 17 33 33 12 95 
Success rates 
% of LOIs invited 
for full proposal  
26.5% 95.5% 79.5% 82.8% 53.8% 
% invited full 
proposals actually 
submitted 
42.5% 96.9% 100.0% 56.3% 76.6% 
% submitted 
proposals 
approved 
54.8% 53.2% 35.5% 44.4% 44.6% 
% of LOIs 
becoming 
approved projects 
6.2% 49.3% 28.2% 20.7% 18.4% 
Source: Phillips and Warren (nd) drawn from Genome Canada. 
Due to the structure of Competition I, its emphasis was primarily on supporting large-
scale projects. In fact, beyond the broad goals of the project proposals being large-scale, 
genome-wide, and in a sector considered important to Canada, there are no explicit 
references to project content at all.  
Competition II provided a lot of details, guidelines and also began to place more of an 
emphasis on GE
3
LS. Whereas the first competition simply asked each centre to have a 
program in place to deal with GE
3
LS related issues, Competition II proposed that projects 
with a strictly GE
3
LS focus as well as science projects with embedded GE3LS research 
could be submitted for funding.
5
 
Competition III was marked with some significant changes in its preamble. GC 
announced it would accept applications from Genome Centers for large-scale research 
projects in genomics or proteomics for either three or four years in duration.
 9
 Genome 
Canada specified that proposals should be of such scale and scope that they cannot 
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currently be funded at internationally competitive levels through other existing 
mechanisms. Each project was now required to have one or more GE
3
LS experts as a co-
applicant, collaborator, or advisory committee member.
7
 Also, an entire section in the 
preamble was dedicated to social and economic benefits of the research.  
The ABC competition further developed the focus on GE
3
LS by providing more detail 
about the format of the plan needed by project proposals to address GE
3
LS issues. It 
directed that project proposals look at how GE
3
LS work could enhance the research and 
realize maximum benefits. The guidelines asked applicants to integrate GE
3
LS issues into 
the scientific components of their proposals, a concept absent from previous 
competitions.
10
The ABC competition guidelines became more precisely worded, 
exchanging words like “economic growth and social benefits” for “product and service 
development.” 11 
 
2.5. Past Evaluations of Genome Canada 
Genome Canada has been extensively reviewed. This section summarizes the nature and 
scope of the various reviews undertaken so far.  
2.5.1.  KPMG Evaluation of Foundations 
This consultancy report, prepared for the Treasury Board Secretariat, presents the 
findings of an evaluation of the use of foundations (i.e. special operating enterprises) as 
instruments of public policy. This study was conducted by KPMG LLP on behalf of the 
Government of Canada between September 2006 and January 2007.  
The study was triggered by the government’s commitments to the Standing Senate 
Committee on National Finance and Standing Committee on Public Accounts to 
undertake an evaluation of the use of foundations as tools for the delivery of public 
policy, particularly with respect to the use of up-front conditional grant assistance. 
Genome Canada and five other foundations were the target of this review.  
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The collection of information for this evaluation relied upon four inter-related lines of 
enquiry, as shown in Figure 2.6 
 
Figure 2.6 KPMG methodology for evaluating foundations 
Source: KPMG LLP, KPMG Report: Evaluation of Foundations, Prepared for Treasury 
Board Secretariat. Ottawa, March 2007.
2
 
This approach was designed to provide information from multiple sources to enable the 
evaluation issues to be assessed from several perspectives and to better understand the 
positions advanced by participants who are most closely involved with the use of 
foundations for public policy purposes.  
The study had to be completed within a relatively short time period (Sept. 2006, to Jan. 
2007), which necessitated a concentrated approach to data collection. 
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The evaluation team started with a review of the broad range of documentation on the 
government’s use of foundations to achieve policy goals, the evolution of the terms and 
conditions under which foundation funding was been provided, and the results achieved 
by various foundations. 
A series of six case studies of selected foundations were used as one of the two core data 
collection and analysis methods in the evaluation. The six case-study foundations were: 
Canada Foundation for Innovation (CFI); Canada Millennium Scholarship Foundation; 
Genome Canada; Aboriginal Healing Foundation (AHF); Green Municipal Fund (GMF); 
and the Pacific Salmon Endowment Fund Society. The case studies were used to obtain 
insights into the appropriateness, effectiveness and costs of specific foundations, which 
were used, in conjunction with findings from interviews with other foundations and 
stakeholders, to identify common characteristics, themes and conclusions applicable to 
most, or all. 
KPMG reported on three aspects of the government’s use of foundations. First, they 
examined the appropriateness of the foundation model as an instrument of public policy, 
concluding that the model exhibited generally strong degrees of alignment with the 
guiding principles published in Budget Plan 2003.
12
Second, they examined the 
effectiveness of the foundations, reporting on their progress against objectives, 
coordination with related government programs, alignment with government policy goals 
and their accountability mechanisms. The general conclusion was that they were doing 
well on all measures, albeit with some range of effectiveness. Third, they examined the 
operating and administration cost structures, focusing on structured and transparent 
processes for reviewing and selecting projects to support, and supporting systems for 
project tracking and financial management. The conclusion was that their operating and 
administration costs are driven by needs to efficiently manage project workloads and to 
provide timely support for governance and accountability requirements. Foundation 
resource levels and costs appear to be closely matched to, or follow, the trends in the 
project workloads. 
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In effect, KPMG offered an organization and operational review of the processes and 
structures, but did not undertake any specific analytical assessment of the fit of those 
processes to the overall goals.  
2.5.2. Risk Management Policy  
Genome Canada developed internally an integrated risk policy as a high level document 
outlining Genome Canada's approach and strategy towards Integrated Risk Management 
(IRM)
13
. Given that a Risk Management Policy must be able to ‘stand the test of time’ 
and be robust enough to withstand scrutiny from regulatory and/or legislative bodies, the 
Policy is broad in scope.  
Risk management includes a risk methodology, risk profiles and related actions that will, 
by nature, change over time to reflect organizational changes and changes in risk profiles.  
The Policy and related risk and action plans are applied to all operational aspects of the 
organization and considers external strategic risks arising from the external operating 
environment as well as other internal operational risks.  
Although Genome Canada is not able to control external factors such as government 
priorities, they are considered and addressed as much as possible. 
Methodology 
 
Figure 2.7 Five-step Genome Canada Risk Management Framework 
Source: Risk Management Policy
13
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This internal policy entails an ongoing series of operational evaluations used to manage 
and safeguard the entity. While critical to effective operations, the Policy involves more 
tactical evaluation than strategic review.  
2.5.3. KPMG Report on Genome Canada 
In 2008 KPMG was contracted by Genome Canada to do an overall evaluation of the 
impact of Genome Canada investments. GC is directed to undertake an evaluation every 
five years as a requirement of their funding agreement with industry Canada. Table 2.8 
provides a breakdown of the large-scale projects and S&T platforms that had been funded 
as of June 3, 2008, broken down by region and sector of application. 
Table 2.8 Funding Allocation 
 
Source: KPMG Report
14
 
This evaluation focused on the impact of the funding allocations. The methodology 
involved a review of internal documentation and databases, web-based surveys and 
interviews and a partial cost-benefit analysis of GC research investments and outcomes. 
As outcomes based approach, the analysis did not directly assess the fit between the 
research funding decisions and the strategic goals of GC. 
2.5.4. Performance, Audit and Evaluation Strategy of Genome Canada (PAES) 
In 2008, Genome Canada articulated a full performance, audit and evaluation strategy 
(PAES); while this updated in 2013, we focus on the earlier version here as it was the one 
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operating during our study period. Figure 2.9 illustrates the elements.
15
 The strategy was 
developed as a high level framework which addresses key elements that Genome Canada 
had implemented or planned to put in place to ensure accountability in the achievement 
of objectives from the perspective of performance, audit, evaluation and reporting. 
 
PERFORMANCE REPORTING 
 
Corporate Plan                               Annual Report                         Special Publications                    Web Site 
PERFORMANCE MONITORING AUDIT EVALUATION 
 
Project Selection 
 
Project Monitoring 
 
Interim Review 
 
Performance Indicators 
 
Final Project Reports 
 
 
Financial Audits 
 
Recipient Audits 
 
Compliance Audits 
 
Performance Audits 
 
Results Based Management And 
Accountability Framework (RMAF) 
 
Logic Model 
 
Evaluations Every Five Years 
 
 
 
RISK MANAGEMENT 
 
Risk Management Framework       Operations and Management         Governance Regime 
Figure 2.9 PAES 
Source: Genome Canada - Performance, Audit and Evaluation Strategy, 2007.
15
 
These processes are designed to contribute to more effective operations and to ensure 
compliance to the funding agreements signed with Industry Canada with respect to the 
use and accounting of funds received from the federal government. Genome Canada also 
signs individual funding agreements with each of the six Genome Centers where the 
undertakings agreed to with Industry Canada are essentially replicated. 
The PAES is comprised of three key frameworks: 1) Performance monitoring and 
measurement; 2) Audit; and 3) Evaluation. All elements provide a foundation for 
strengthening internal management.  
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2.6. Implications for this research  
As reviewed above, while there have  been some efforts to assess the operations of the 
organization related to its goals and objectives, this work has been mostly in the form of 
institutional audits and qualitative assessments. This study extends that work. It offers an 
empirical, quantitative assessment of the fit between the institutional goals and objectives 
and the funding allocations of the organization to determine the relative balance and 
impact of the diverse objectives on their core activity of funding research.   
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3. Evaluation in the Policy Literature 
3.1.  Definition 
Evaluation is a critical part of the public policy system, as it helps to define problems, 
delimit options, aid with decision making and improve operational efficiency.  Evaluation 
is defined as the systematic determination of merit or worth using criteria against a set of 
standards.
16
 
At the individual level, evaluation can be the formal determination of an individual's job-
related actions and their outcomes within a particular position or setting. In financial 
trading, its objective is to assess the extent to which an individual added wealth to a firm 
and/or its clients, and whether his or her achievement was above or below the market or 
industry norms, also called measurement.
17
  
At the organizational level, evaluation is a critical link in Simon's (1997) ends-means 
causal chains.  Only with organizations, the focus is on how specific activities or 
processes contribute to the goals of the institution or agency.  
The design of a particular evaluation approach depends on the actors involved and the 
situation.
15
 Standards and principles of evaluation give some sense of direction and the 
base of ethical norms, commitment and integrity. In our study, the stated goals of GC are 
the foundation of the whole process for project evaluation. 
In the Government of Canada, evaluation is the systematic collection and analysis of 
evidence on the outcomes of programs to make judgments about their relevance, 
performance and alternative ways to deliver them or to achieve the same results. 
Evaluation provides Canadians, Parliamentarians, Ministers, central agencies and 
organizational heads an evidence-based, neutral assessment of the value for money (i.e. 
relevance and performance) of federal government programs.  
Evaluation: 
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a. supports accountability to Parliament and Canadians by helping the government 
to credibly report on the results achieved with resources invested in programs; 
b. informs government decisions on resource allocation and reallocation by: 
i. supporting strategic reviews of existing program spending, to help 
Ministers understand the ongoing relevance and performance of existing 
programs; 
ii. providing objective information to help Ministers understand how new 
spending proposals fit with existing programs, identify synergies and 
avoid wasteful duplication; 
c. supports deputy heads in managing for results by informing them about whether 
their programs are producing the outcomes that they were designed to produce, at 
an affordable cost; and, 
d. supports policy and program improvements by helping to identify lessons learned 
and best practices.
18
 
Evaluation products means any output of the departmental evaluation function, which 
may include, but is not limited to, the departmental evaluation plan, terms of reference 
for individual evaluations, evaluation assessments, evaluation frameworks, evaluation 
reports, and advice.
18
 
 
3.2. Literature Review 
In an early paper on performance evaluation, Arvidsson (1986)
 
focused on the pressures 
facing public services. He asserted that government performance evaluation could be 
measured in several ways, either by examining objectives, timing and the procedures of 
international administration.
 19
 
 20 
 
King (1987) asserts that research evaluation “makes use of a variety of indicators to draw 
as complete a picture as possible of the complex aspects that account for the performance 
of research”.20 
 
Peter Henry Rossi (2004) defined program evaluation as the use of social research 
procedures to systematically investigate the effectiveness of social intervention programs, 
adapted to the political and organizational environments and designed to inform social 
action in ways that improve social conditions. Comprehensive evaluation is an 
assessment of a social program that covers the need for the program, its design, 
implementation, impact, and efficiency. 
21
 
The differences between policy analysis and policy evaluation are widely known but 
increasingly unrecognized. Geva (1999) compares policy evaluation and policy analysis 
in terms of concept, methodology, problems and data description. Evaluation tends to 
adopt a focus on the analyst/process which is being used to make policy choices.
22
  
Theory-based evaluation (TBE) has become widely discussed and occasionally practiced 
in the recent years. Birckmayer (2000) 23 identified evaluations may be needed beyond the 
regular operational assessment. Supporters think this approach will help to explain how 
and why formal project assessments predict the results. Very often, this type of 
evaluation will follow each step in a sequence to see whether the expected steps actually 
occurred. 
 
Figure 3.1  Treasury Board of Canada Outcomes Management Framework 
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One way to look at the challenge of evaluating research systems is through an outcomes 
management framework, as shown in Figure 3.1. In this context, it is possible to see that 
evaluation could focus on efficiency and effectiveness, with efficiency analysis 
investigating the causal path between inputs, activities and direct outputs. With respect to 
Genome Canada, the inputs could be viewed as the allocation of funds from Industry 
Canada, as illustrated in Figure 2.3. The focus of this work is on the 'activities' 
undertaken by Genome Canada to allocate funds to specific science projects (the outputs). 
Luukkonen (2002) notes that research evaluation also is connected with the assessment of 
performance of applicants and on the embedded decision-making sub-systems, such as 
peer review.
24
  
Michael Quinn Patton (2002) asserts “a successful evaluation emerges from the special 
characteristics and conditions for a particular situation—a mixture of people, politics, 
history, context, sources, constraints, values, needs, interests, and chance. Despite the 
rather obvious, it is not at all obvious to most stakeholders who worry a great deal about 
whether an evaluation is being done right. Indeed, one common objection stakeholders 
make to getting actively involved in designing an evaluation is that they lack the 
knowledge to do it right.”25  
 
3.3. Overview of Evaluation Methods 
In essence, performance evaluation is described as comparing results against objectives, 
which will vary with different situations. It could also be applied in many ways. Here is a 
list of various evaluation methods (table 3.3). 
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Table 3.1 Characteristics of Evaluation Methods 
Methods Description 
Peer review/expert 
judgment 
Qualitative review, opinion, and advice from experts on the subject 
being evaluated based on objective criteria 
Case study Information through a narrative about the subject 
Historical tracing 
A series of interrelated events either going forward from the research of 
interest to downstream outcomes or working backward from an 
outcome along a path that is expected to lead to precursor research 
Network analysis 
Visual mapping and measurement of relationships and linkages among 
researchers, groups of researchers, laboratories, or other organizations 
Benchmarking 
The systematic comparison of practice, status, quality, or other 
characteristics of programs, institutions, regions, countries, or other 
entities using a selected set of performance measures 
Survey 
Obtaining information directly from people about their ideas, opinions, 
attitudes, beliefs, preferences, concerns, plans, experiences, 
observations, and virtually any other issue; interviews, document 
review, literature review 
Technology 
commercialization 
tracking 
The new energy-efficient technologies developed through R&D projects 
sponsored by the program, which may include research cost-shared with 
an industry 
Benefit-cost case 
study 
Applied research and technology programs with well-defined goals that 
lend themselves to at least partial economic interpretation and analysis, 
though assessed benefits and costs often extend beyond economic 
effects 
Econometric 
methods 
A variety of statistical and mathematical tools and theoretical models to 
analyze and measure the strength of functional relationships that 
underpin a program and to analyze and measure a program’s effects on 
firms, industries, innovation, and the economy 
Source: USA Department of Energy (2007).
26
  
To date, Genome Canada has used a range of these methods. The most prominent choices 
have been document review, peer review (used for competition I, II, III, ABC)  and case 
study. The KPMG Evaluation of Foundations evaluation team reviewed a broad range of 
documentation on the government’s use of foundations to achieve policy goals, the 
evolution of the terms and conditions under which foundation funding has been provided, 
and the results achieved by various foundations. They also undertook case studies to 
obtain insights into the appropriateness, effectiveness and costs of specific foundations. 
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The internal processes detailed in Chapter 2, Figures 2.2 illustrate the role of historical 
tracking in assessing the system. KPMG's review in 2009 used a mixed method approach, 
including peer-reviewers, expert judgment, survey and benefit cost.  
Our study applies some of the insights from the econometric approach exemplified by 
Lusk to empirically evaluate the fit between goals an allocation decisions in the context 
of the open competition and internal project development processes. By testing several 
factors, we intend to evaluate the relationship between the chosen projects and stated 
goals of each funding initiative. To date, econometric methods have not been applied 
directly to the Genome Canada investments. In other areas, these tools have been widely 
used to identify the causal links between inputs and outputs.  Lusk et al (2005), for 
example, used a meta-analysis to evaluate the impact of consumer willingness-to-pay 
(WTP) or willingness-to-accept (WTA) values for various novel food products. The goal 
is to generate a set of findings about consumer WTP/WTA for food that are based on the 
results of a single study, but to provide policy makers with a nuanced summary of a body 
of work. “For example, a dummy variable was created to identify whether the valuation 
was from a study that strictly elicited WTA.
 
Finally, several variables were created to 
describe the good valued in each of the studies, including the food type and whether the 
food provided any direct benefit, such as enhanced nutrition, to the consumer”. 27 
Narongrit (2010)
 
used grouping method and pilot 3D location as an evaluation method to 
assess academic ranking as a means of allocating resources. The Office of the Higher 
Education Commission (OHEC), Ministry of Education in Thailand had considered the 
university rankings to be measured among the academic community, in the purposes of 
assigning budget allocations for academic promotions. 
28
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4. Methodology, Model & Data 
4.1. The Logic of the Model 
This chapter lays out the logic for assessing the operational fit between Genome 
Canada’s investment program between 2001 and 2012 and the organizational mandate.  
The basis assumption is that we will find a positive and significant fit between the goals 
and the nature of the funding allocations.  
The goal is to undertake a strategic analysis. In order to model the process appropriately, 
we have laid out the Genome Canada process logic.  
Figure 4.1 Logic of the Process 
The funding agreement between the  Government of Canada and Genome Canada lays 
out the organizations objectives. Those objectives are taken as high level criteria by 
which the organization will allocate the funds provided to GC.  
The government's overall science and technology policy goal is the production of 
scientific knowledge and the advancement and commercialization of technical knowledge.  
From 2000 to 2012, the specific objectives of Genome Canada are: (1) developing and 
implementing a coordinated strategy; (2) bringing together industry, governments, 
Government sets 
policy goals 
Objectives of 
Genome Canada 
GC raises capital 
from government 
GC sets up 
competitions with 
stated objectives 
Open competition 
 GC facilitates 
proposals and 
assembles 
candidates 
External peer 
review 
Projects approved 
Project deliver 
results 
Project attributes 
assessed & 
compared to 
stated criteria 
Adjusted key 
factors to meet 
the policy goals 
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universities, research hospitals and the public to support large-scale genomics and 
proteomics research projects; (3) providing accessibility to Science & Technology 
Platforms to researchers; (4) assisting in attracting co-funding for projects from both 
domestic and international investors; and (5) sustaining leadership. 
2
 
Those goals then translate into five core objectives that should be reflected in the funding 
allocation decisions:
29
 
Objective 1 is to develop and implement a coordinated genomics research strategy. In 
practical terms, this translated into a series of internal processes to assess and identify 
coordinated strategies for genomics research to enable Canada to become a world leader 
in areas such as sector health, agriculture, environment, forestry, fisheries, tech and 
GE3LS. 
Objective 2 is about providing leading-edge technology. Operationally, this involves the 
provision of leading-edge technology to researchers in all genomics-related fields.  
 Objective 3 is to support large-scale research. In effect this is a scale issue. Given the 
nature of the Genome Canada database we have generated (i.e. not including the projects 
that were rejected), we cannot show this effect inside our data. One way to see scale is to 
compare the allocations by Genome Canada with allocations on genomics-related 
research by the Canadian Institutes for Health Research (CIHR) and the Natural Science 
and Engineering Research Council (NSERC). Data in table 4.1 shows the average size of 
GC allocations are about 10 times the size of the average CIHR grant and about 65 times 
larger than comparable awards by NSERC. 
Table 4.1 Grants for genomics related research, 1999-2012 
 Granting 
Period 
# projects 
funded 
Total value of direct 
outlays 
Average 
$000/project 
CIHR 1999-2014 1370 $572.1 M $ 417.6 
NSERC 1999-2012 1130 $ 75.2 M $ 66.5 
GC 2001-2012 156 $ 682.6 M $4,375.5 
Source: Author's calculations using data derived from the CIHR and NSERC Funding 
Decision Databases, Aug. 6th, 2013  Objective 4 is to assume GE3LS leadership and to 
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communicate more effectively with Canadians. The assumption of leadership in the area 
of ethical, environmental, economic, legal, social (GE3LS) and other issues related to 
genomics research and the communication of the relative risk, rewards and successes of 
genomics to the Canadian public can be assessed by the role and position of GE3LS in 
the structure of each competition and in the related projects.  
Objective 5 is to encourage investment by others. In practice, this can and should be 
measured by whether the projects leverage co-funding from non-governmental sources, 
including international sources. 
The purpose is to explore the influence of key factors in the selection and allocation of 
funds to projects.  
While we are ultimately concerned about efficacy and accountability of the choice 
systems used by Genome Canada, the key processes are not directly measureable—they 
are effectively in a black box. Nevertheless, they are the indirectly discernible through 
examining the information available at the time of the decision making and the resulting 
allocations of funds.  
An econometric approach was used to fit proxies for the stated objectives to the share of 
the portfolio allocated to each project. . 
A series of regressions will be employed to determine the proportion of the funding 
allocations that are explained by the objectives. The residual could be interpreted as the 
influence of soft factors, like the personal preference of the reviewers and Genome 
Canada staff, the cognitive bias of the various decision makers, the context of the specific 
science platform and the uncertain environment. 
4.2. Data Sources 
As shown in table 2.4 in chapter 2, Genome Canada has engaged in four large-scale, open 
research competitions, commonly named competitions I, II, III and the Applied 
Genomics in Bio-products and Crops (ABC) competition, and the other competitions. 
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The funding data is mentioned in chapter 2. As of 2012 Genome Canada had committed 
$915 million in funding and researchers had secured approximately an additional $1,085 
million in co-funding, representing a total investment of over $2 billion in completed or 
planned genomics research in Canada. We have used that data, allocated by specific 
project, to calculate project shares of funding and used this as the dependent variable.   
The independent variables that are assessed for fit with funding decisions are discussed 
below. 
4.3. Basic Equation 
The basic equations in the model involve running regressions with the allocation 
decisions as the dependent variable and the key organizational and program objectives as 
the independent variables.  
The basic estimation equation is: 
Y= a + b1*GE
3
LS + b2*Technology + b3*International co-funding + b4* PI 
reputation + b5*Institution research intensity + bx* competition, section and 
regional dummies 
(4.3.1) 
The following variables have been chosen to describe the potential relationship between 
the different variables.  
4.4. Dependent Variables    
Two dependent variables have been tested, that is Y1 (GC-total) and Y2 (Open-com). The 
regression using the total pool of investments provides insights into the performance of 
the organization across the portfolio of investments. This portfolio is chosen through two 
discrete systems. The main portion of the funding is allocated through open competitions, 
where investigator-led teams submit competitive proposals that are adjudicated through a 
competitive peer-review process. The rest of the portfolio involves directed projects, 
where Genome Canada, one of the regional centres or a partner has developed a project to 
fit a specific strategic or tactical need. These projects are internationally peer-reviewed 
but there is little in the way of competition in the process. The second regression tests to 
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see how the choices in the open competitions conform to the stated goals of Genome 
Canada. By reduction, any difference in fit between the open competitive process and the 
overall pool would tell us something about the efficacy of the process of developing 
directed projects  
Table 4.2 Explanations of dependent variables 
GC-goals 
Objective 
Subject Unit Description Calculation Source 
Allocation 
of Fund 
Y1: GC-total % 
% share of GC contribution of 
each project in the total fund pool 
of all Genome Canada 
contribution 
   
        (%)  
(i~[1,156], 
n=156) 
Genome 
Canada 
Reports
1
 
Y2: Open-
com 
% 
% share of GC contribution of 
each project in the open pool of 
GC contributions in I, II, III and 
ABC competitions. 
          (%)  
(i~[1,95], 
m=95) 
The percentage share of each project in the total fund pool is a way to measure the 
allocation of funding. That is for each project, the assigned fund will share Yr% of the 
funding pool in both the total and open competitions.  
The subject Y1 GC-total is the percentage share of GC contribution of each project in the 
total fund pool of all Genome Canada contributions. This pool involves 156 projects 
which shared $683 million funds invested by Genome Canada. It is calculated as the GC 
contribution dollar of each project (Ai) as a percent of entire portfolio. While Genome 
Canada has invested $996 million, about one third of the commitments and disbursals is 
for infrastructure and operations and not to fund research projects. 
The subject Y2 open-com is the percentage share of GC contribution of each project in 
the open pool of GC contributions in Competitions I, II, III and ABC. From the 
calculation, we could know that the total open pool         (i~[1,95], m=95) equals 
$485 million. Ai is the GC contribution of each project. 
4.5. Core Independent Variables 
Five core variables have been identified as conforming to four of the objectives: 
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Table 4.3 Explanations of Behavior Independent Variables 
GC-goals 
Objective 
Subject Unit Description Calculation Source 
(a) Sustain 
leadership 
and 
coordinated 
strategy 
X1 
PI (lead 
Harzing 
index) 
Index 
Principal 
Investigator(PI) 
research capability: 
measured by HI 
index (collected by 
2012.7) 
Lead Harzing 
Index-HI 
Index 
www.harzing.com 
X2 Research 
intensity 
dollar 
Host institution 
research capability: 
measured by Total 
Research Dollars 
(10000$ per full-
time faculty 
member) 
Total 
Research 
Dollars 
(10,000$ per 
full-time 
faculty 
member) 
 
Appendix II  
(b) Support 
GE3LS 
X3 
GE3LS 
 
Whether the 
project supports 
GE3LS 
Yes=1; No=0 
 
 
 
 
 
 
Genome Canada 
Reports 
1 
 
(c) 
Encourage 
PPP (public-
private 
partnership) 
X4 
International 
co-founding 
 
International co-
funding source  
Yes=1; No=0 
(d) Provide 
leading-edge 
technology 
X5 
Technology 
 
Whether the 
project is in a 
technology 
development 
activity and 
represents the 
leading-edge 
Yes=1; No=0 
4.5.1. PI and Research Intensity as a measure of Leadership 
The coordinated genomics research strategy is designed to support leadership, which is 
assumed for this analysis to be represented by the Principal Investigator's (PI) research 
capability measured by the Harzing Index (HI) index (X1) and a variable that measures 
the research intensity of the host institution (as measured using the MacLean's research 
funding measures) (X2).  
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The HI index (X1) was proposed by J.E. Hirsch
30
 in a paper entitled “An index to 
quantify an individual's scientific research output".
1
 It is defined as follows: “A scientist 
has index h if h of his/her Np papers have at least h citations each, and the other (Np-h) 
papers have no more than h citations each.” It aims to measure the cumulative impact of a 
researcher's output by looking at the amount of citations among the most highly cited 
parts of his/her work. The calculation tool Publish or Perish
2
 calculates and displays the h 
index proper, its associated proportionality constant a (from Nc,tot = ah
2
), and the rate 
parameter m (from h ~ mn, where n is the number of years since the first publication).  
One option to see the trend is through a scatter-plot. Using the scatter-plot procedure, (by 
typing scatter yvar xvar, || lfit yvar xvar) we generated a scatter-plot with PI along Y1 
GC-total and Y2 open-com.  
 
Figure 4.2 Y1-GC-Total along PI 
                                                 
 
1 arXiv:physics/0508025 
2 The properties of the h-index have been analyzed in various papers; see for example Leo Egghe and Ronald Rousseau: 
An informetric model for the Hirsch-index, Scientometrics, Vol. 69, No. 1 (2006), pp. 121-129. 
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Estimated Y1= 0.484 + 0.0157*(PI) 
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From Figure 4.2, the assumption of the positive relationship between PI and Y can be 
seen on the fitted values. The regression results are shown below.  
 
Figure 4.3 Regress GC-total PI  
 
            Estimated Y1= 0.484 + 0.0157*(PI)                        (4.5.1.1) 
(8.49)*** (3.81)***        
 
This equation tells us that, all other things being equal, for every 1 unit increase in PI HI 
index, Y1 is expected to increase by 1.57%.   
Limiting the analysis to the open competitions, we find the slope and the intercept are 
statistically significant at 98% and 99% confidence interval respectively. For every 1 unit 
increase in HI, Y2 is expected to increase 2.74%. Using the adj-R
2
 we can see that about 7% 
of the variance in Y2 is explained by the PI HI indicates.  
Another way is to look at the individual variable character through descriptive statistics. 
Appendix I present the results of a histogram and codebook analysis. The codebook and 
histogram shows the “feel” of the PI. In this case, the PI HIs range from 0.2 to 53. The 
mean is not near the centre of the range; it is located at the end of first quarter of the 
range. Almost 90% of the index numbers were in the bottom half of the range. The 
distribution is not equal, which means it is not normal distribution. 
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Figure 4.4  Y2 Open-com 
 
 
Figure 4.5 Regress Open-com PI 
 
Estimated Y2= 0.855 + 0.0274*(PI)                        (4.5.1.2) 
(8.47)***   (2.58)** 
 
A second factor is institutional leadership. Given that one of the stated objectives of 
Genome Canada is to generate globally competitive research capacity, it would be 
0
1
2
3
0 10 20 30 40 50
Lead Hazing index
Funding_share (open-com) Fitted values
Estimated Y2= 0.855 + 0.0274*(PI) 
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appropriate to assess whether prior institutional capacity is influential in determining the 
allocation of funds. The relative research intensiveness of the host institutions, as 
measured through the MacLean's institution research reports (X3) is one way to rank the 
host institution research capability (see Appendix II).  
The annual Maclean’s3 rankings assess Canadian universities on a range of performance 
indicators in six areas. We chose the Total Research Dollars reported in Maclean’s 
(including income from sponsored research such as grants and contracts, federal, 
provincial and foreign government funding, and funding from non-governmental 
organizations) adjusted for the relative size of each institution (i.e. using a capitation 
formula based on full-time faculty). 
The indicator Resources-Total Research Dollars is chosen to evaluate the research 
capability of the host institution, which is then rebased to 10,000 dollars per full-time 
faculty member. From the codebook in appendix II, the range of this variable is 0.43 to 
3.51, with a mean of 2.51. 
4.5.2. GE3LS 
Objective 4 asserts GC seeks to generate leadership in the area of ethical, environmental, 
economic, legal, social (GE3LS) and other issues related to genomics research and the 
communication of the relative risk, rewards and successes of genomics to the Canadian 
public (X4). Projects can either embody integrated research (INTERGE3LS) or can be 
stand alone.  This is a dummy variable with a value of 1 if GE3LS is embodied in some 
way in the project and zero otherwise. Of the 156 projects, 11 are stand-alone GE3LS 
projects and 50 are INTERGE3L.  
4.5.3.  Leveraged co-funding as Public-Private-Partnerships (PPP)  
Genome Canada established ambitious co-funding goals for their projects. The minimum 
threshold was 100% matching, in cash or in kind. All approved projects by definition met 
that goal. Over the past decade, GC has attracted $1 billion in co-funding to complement 
                                                 
 
3 http://tools.macleans.ca/ranking2008/selectindicators.aspx 
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the $980 million committed by the Government of Canada.
4
 There is little difference in 
leveraging among projects. 
We were particularly interested whether public-private partnerships (PPPs) were 
influential. To test that, X5 was defined as the presence of investment by an international 
co-founder. Projects with identified international partnership were coded one; projects 
with only domestic funding were coded zero.  
4.5.4. Technology 
The variable Technology (X6) corresponds to objective 2, providing leading-edge 
technology. In the final report of Genome Canada, it tests whether the project is deemed 
to be in the "technology category" or not.
1
 It is determined by the category factor, which 
could shown in the GC Database (in appendix VI). Operationally, X6 involves the 
provision of leading-edge technology to researchers in all genomics-related fields through 
regional Genome Centers across Canada, which represents objective 2. 
4.5.5. Regional, sectoral and competition dummies 
Given that there were four competitions and the directed investments, seven priority 
research areas and six geographic regions, it is possible that context may have been a 
determining factor in the funding allocations. Table 4.4 shows how those factors have 
been converted into dummies to control for these technical factors. The only significant 
change we made was to combine Genome Alberta and Genome Prairie, on the basis that 
their activities were highly correlated; Genome Prairie, located in Edmonton, served the 
three Prairie Provinces until 2005, when Genome Alberta became an independent centre 
and Genome Prairie moved operations to Saskatoon. Since then they have collaborated 
closely on development and management of a range of successful projects, making it 
problematic to include them as fully independent contextual variables.  
 
                                                 
 
4 2012 Annual Report of GC 
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Table 4.4 Description of Dummies 
Part Variable = 1 Description 
Calculation 
(Freq.)
5
 
mean 
% of 
fund 
Sector 
Health  82 0.52 62.26% 
Agriculture  16 0.096 8.55% 
Environment Environment, energy, fishery 19 0.09 15.53% 
Forestry  11 0.071 6.21% 
Technology 
Providing leading-edge 
technology 
18 0.115 4.14% 
GE3LS 
The research on the ethical, 
environmental, economic, 
legal and social (GE3LS) 
aspects of genomics. 
11 0.071 3.32% 
Region 
BC 
 
40 0.256 22.64% 
Prairie 
Alberta, Saskatchewan and 
Manitoba 
21 0.134 15.61% 
ON 
 
52 0.339 37.06% 
Quebec  34 0.218 21.15% 
Atlantic  8 0.051 3.59% 
Competition 
category 
com1 Competition I 17 0.109 11.82% 
com2 Competition II 33 0.212 21.43% 
com3 Competition III 33 0.212 29..99% 
ABC 
Applied genomics research in 
Bio-products or Crops(ABC) 
12 0.077 7.77% 
Directed 
competitions 
Other categories 61 0.391 28.99% 
Total  
  
156 
  
Source: Appendixes codebook and sum 
Note: Tab X- STATA command in having Frequency and Percentage 
                                                 
 
5 Codebook-STATA, Appendixes III 
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     Sum X- STATA command in having mean 
     % $ of the fund is calculated by the original data in excel  
From the above Table 4.4, the sum of dummies for each category above equals to one, as 
all variables cover all the possibilities in each category. For example, a project by 
definition must be in one of the regions (British Columbia, the Prairies, Ontario, Quebec 
and the Atlantic), sectors (health, agriculture, environment, forestry, tech, GE3LS) and 
Competition category (com1, com2, com3, ABC, Directed). To avoid over definition of 
the regression, at least one variable from each category is excluded in each regression. In 
the end, the extra detail offered by the six regions, seven sectors and five competition 
categories did not add much descriptive power. While all of the dummies are presented 
here and in tables 5.1 and 5.2, the regression results presented in tables 5.5 and 5.6 only 
involve the single largest variable in each category (i.e. Ontario, health and directed 
projects).Before exploring the relationship between funding share and project character, 
the whole data set was built using the above rules. The dataset of 156 projects is called 
data-full and is included in appendix VI. 
Once the dataset was constructed, STATA (version IC/11.1) statistical package was used 
to estimate regressions.  
The first step, even before running any multivariate regression, was to look at the 
individual variables and their distributions. To do that we looked at the histograms kernel 
density curves as presented in the appendixes. These show that most of these variables 
are not normally distributed.  
Therefore we ran the ladder test for individual variables using the chi-squared test to 
identify the closest normally distributed transformation (Appendix IV). One of the ways 
to correct for this is to transform one of the variables. We chose to test whether a 
transformation would help. We transformed the PI variable into a log form (i.e. generated 
LGPI= log (PI)). The log transformation is a monotonic transformation, which keeps the 
order of the numbers, while transforming the distribution of the observations.  
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From the histogram of the two variables PI and log PI (Figure 13), we can see that the 
distribution of log PI is closer to normal distribution, compared to the skewed distribution 
of PI. Looking at the summary of both variables, we can see the standard deviations are 
much smaller for log PI. Using this information, we transformed PI and did regressions 
on each of them (see Appendix IV Figure 5).
6
 Comparing the regression results from 
non-transformed variables with transformed variables, we found that the overall model fit 
(R
2
) deteriorated 12% to 2.6%, so that the above transformed was not used in the formal 
regressions that follow. 
The OLS method is chosen to estimate the model for two reasons. First, the lack of any 
obvious correlations between the independent variables suggests that the variables may 
be independently considered in the decision system. Furthermore, there was no obvious 
direction or effort to differentially assess and apply the independent variables in the 
decision system—i.e. Genome Canada does not direct specific weights be used nor does 
it provide any architectural design to the consideration of these variables. All variables 
are considered equally in the decision system, with weights being revealed through 
choice rather than assigned a priori. Thus, in absence of any other evidence to the 
contrary, the OLS was chosen as the most appropriate method of calculating the influence 
of these variables on the overall decisions.  
  
                                                 
 
6 Appendixes Figure 14 Comparison of regression on PI and Log PI 
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5. Empirical Analysis & Regression 
This section presents and discusses the multivariate model results. 
5.1. Correlation Test 
There were a number of issues that came up during the multivariate model building phase. 
Before testing the relationship between the Xi and Y, we tested to determine whether the 
independent variables were correlated and involve the risk of multicolinearity. The 
correlation matrix in Figure 5.1 is the test. 
 
Figure 5.1 Correlations matrix for independent variables 
Multicolinearity is a risk in these kinds of analysis. If one or more of the independent 
variables are significantly correlated with each other, it would not necessarily reduce the 
overall explanatory power (R
2
) of a regression but it might significantly change the 
assigned impact of the explanatory power of the independent coefficients.  
For the 156 examples, the t –stat which matches 90%, 95%, 99% significance level is as 
the following table 5.1.  
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If the correlation coefficient exceeds certain number shown in the table, then there is the 
potential for multicolinearity. 
Table 5.1 Critical values for significant correlations 
dF=155 Significant T Correlation 
coefficient  
90% 1.65 0.132 
95% 1.98 0.157 
99% 2.61 0.206 
Source: Author's calculations 
The regional dummies for BC and Ontario have a correlation coefficient of -0.4251, 
which means that the two variables are significant negatively correlated. We have 
controlled for this by leaving the Ontario dummy out of the regression.  
The fishery dummy is also significant positively correlated with the Atlantic region 
(+0.4205). The reason is that the activity related to the fisheries is too small (with only 3 
projects) and almost half of the fishery program is in Atlantic. 
The solution chosen was to combine fisheries with environment. Removing those two 
variables from the analysis solves most of the significant correlations (see figure 5.2). 
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Figure 5.2 Correlation matrix for independent variables (fixed data) 
The further matrix is made under the estimated model which only show the used dummy 
and variables, chosen was under the logic of the final regression (Model D in table 5.4). 
 
Figure 5.3 Correlation matrix for independent variables (model D in table 5.4) 
 
5.2. The Basic OLS & Model Building 
At this point it would be a good idea to see the structure of the models that are evaluated 
(see table 5.3), and the summary statistics which has been used in the following OLS. 
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Table 5.3 Independent Variable Description 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Summary Statistics 
In effect, we test a number of configurations of consolidating or unpacking various 
dummy options to find the best fit. All of the regressions include the core independent 
Independent variable  
Number Category Variable 
VAR1 Leadership PI 
VAR2 Investment Maclean research index 
VAR3 Partnership International co-funding 
VAR4 GC strategy interGE3LS 
VAR5 
Sector 
health 
VAR6 agriculture 
VAR7 environment 
VAR8 forestry 
VAR9 Technology 
VAR10 GE3LS 
VAR11 
Competition 
com1 
VAR12 com2 
VAR13 com3 
VAR14 ABC 
VAR15 Directed 
VAR16 
 
Region 
BC 
VAR17 Prairie 
VAR18 ON 
VAR19 Quebec 
VAR20 Atlantic 
R
2 
(%) for regression Y1 GC-total,  Y2 open-com  
N=156 
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variables; the PI-HI measure, the Maclean's ranking, the dummy for GE3LS and the 
technology variable.  
The models are designed under the logic after table 5.3. Apart from the four core 
independent variables, the PI-HI measure, the Maclean's research ranking index, 
international co-funding, interGE3LS for the strategy, the dummy is added in an order to 
see the changed R
2
 of the process.  
Table 5.4 Multivariate Model building 
Independent variables 
 
Model 
A 
Model 
B 
Model 
C 
Model 
D 
Leadership indicators:  
PI 
√ √ √ √ 
Investment indicators:  
Maclean Research index 
√ √ √ √ 
Partnership indicators:  
International-co-funding 
√ √ √ √ 
GC Strategy indicators:  
INTER-GE3LS 
√ √ √ √ 
Dummies for SECTOR:  
Health 
 √ √ √ 
Dummies for COMPETITION:  
 Directed 
  √ √ 
Regional dummies 
ON 
   √ 
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5.3. Regression of Y-GC total 
We can see that as we expand the scope of dummies, the overall model fit increases and a 
larger share of the allocation of funds is explained by the evidence available at the time of 
the decisions. In this sense, the model helps to quantify the relationship between the goals 
and allocations of Genome Canada.  
 Table 5.5 presents the results of estimating OLS with Y-GC total as the dependent 
variable. 
Four separate regressions are presented; others with more dummy variables were 
estimated but they did not improve the fit and are not included here. 
Table 5.5 OLS estimation result on Y-GC total (Detailed table see Appendix V) 
Dependent Variable Y-GC total 
Independent Variable Model A Model B Model C Model D 
Intercept 0.21 0.16 0.18 0.32** 
Leadership indicators:  
PI 
0.01*** 0.01*** 0.01*** 0.02*** 
Investment indicators:  
Maclean research index 
0.06 0.03 0.02 0.007 
Partnership indicators:  
International co-funding 
0.23*** 0.2** 0.2** 0.21*** 
GC Strategy indicators:  
Inter-GE3LS 
0.26*** 0.25*** 0.26*** 0.19** 
Dummies-SECTOR: 
Health 
 0.3*** 0.3*** 0.26*** 
Dummies-REGION:  
ON 
 
 
0.05 0.07 
Dummies -COMPETITION:  
Directed 
 
  
-0.41*** 
Number of observation 155 155 155 155 
F Statistics 7.75 9.97 8.33 12.80 
Adjusted R
2
 0.15 0.23 0.22 0.35 
Significance levels (p value): * p<0.1; ** p<0.05; *** p<0.01 
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Model D fit the highest R
2
. The basic equation which follows the objectives stated in GC 
in Regression Y-GC total is as following:  
 
Y=0.32 +0.02*(PI) +0.007*(Research) +0.21*(International) +0.19*(INTERGE3LS) 
   2.40** 4.69***   0.14             2.77***            2.51**           
 +0.26*(Sector-health) +0.07*(Region-ON) -0.41*(Directed)      
3.79***            0.92              5.46***                      (5.3.1) 
 
We will interpret the result based on Model D, but also discuss results of the other 
models. 
We see that the intercept term is equal to 0.32, which means the funding share of a 
project in total fund pool of competitions when the value of all other independent 
variables are equal to zero would be 0.32% (significant at 95% level). 
Moreover, on average, a project’s Principal Investigator (PI) reputation, measured by the 
HI index, increases the project share by 0.02% for each unit increase index in HI 
(significant at 99.9% level), other things being equal. 
The host institution also has little effect. On average, the share of GC contribution to each 
project in the total pool of all Genome Canada contributions will increase 0.007 for each 
additional index point (not significant). The project’s host institution of research 
capability index is measured by total research dollars per full time faculty member 
(10000$ ). On average, projects with international co-founding share approximately 0.21% 
(99% confidence level) more than a project which has matching funds only from 
domestic sources, other things being equal.  
Moreover, on average, an INTER-GE3LS project is expected to have approximately 0.19% 
(95% confidence level) more than a project which is not, other things being equal.  
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Moving on to the coefficient for sector, on average a health project is expected to have 
approximately 0.26% (99.9% confidence level) more than a project which is not, other 
things being equal.  
For the Region dummy, on average, a project in Ontario is expected to have 
approximately 0.07% (not significant) more than projects which are not in Ontario, other 
things being equal. In short, there is no special regional bias. 
A project which is not from Com I, II, II and ABC (i.e. directed-com) is expected to share 
approximately 0.41% (99.9% confidence level) less than an open-competition project, all 
other things being equal. In short, the open competition grants were larger. 
Model D contains more detailed dummy variables, such as the regional dummies, the 
sector dummies and the competition dummies as the adj-R
2
 reaches up to 35% for these 
regressions.  
Other more specified models were calculated but the adj-R2 did not improve measurable. 
Given Occam's razor that the simplest explanation that explains the most is best, and the 
principles of parsimony, economy and succinctness, Model D was chosen, as it used the 
least variables to explain the most. 
 
 
5.4. Regression of Y-open com 
Three of the many regressions attempted are reported here. Those with more dummies 
were rejected as they did not materially improve the fit. 
Since the Y-open com regression is only about the open review process, the competition 
dummy is not suitable to test in this section. 
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Table 5.6 OLS estimation result on Y-open com 
Dependent Variable Y-open com 
Independent Variable Model A Model B Model C 
Intercept 0.57** 0.52** 0.65*** 
Leadership indicators:  
PI 
0.02* 0.02 0.02* 
Investment indicators:  
Maclean rank 
0.07 -0.00 -0.09 
Partnership indicators:  
International co-funding 
0.27* 0.21 0.20 
GC Strategy indicators:  
Inter-GE3LS 
0.26* 0.29** 0.28** 
Dummies-SECTOR: 
Health 
 0.47*** 0.48*** 
Dummies-REGION:  
ON 
 
 
0.30* 
Number of observation 94 94 94 
F Statistics 3.27 5.65 5.47 
Adjusted R
2
 0.15 0.20 0.22 
Significance levels (p value): * p<0.1; ** p<0.05; *** p<0.01 
 
The model D fit the highest R
2
. The basic equation which follows the objectives stated in 
GC in Regression Y-open com is as following:  
 
Y= 0.65    + 0.02 * (PI)  - 0.09 * (Research)  + 0.2 * (International)  
   2.74***  1.77*       0.97                1.44                
 +0.28 * (INTERGE3LS)  +0.48 * (Sector-health) + 0.3 * (Region-ON) 
    2.10**            3.81***          1.92* 
                                        (5.4.2) 
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We see that the intercept term is equal to 0.65, which means the funding share of a 
project in open pool of competitions (I, II, III, ABC) when the value of all other 
independent variables are equal to zero would be 0.65% (significant at 99% level). 
Leadership continues to matter. On average, the quality of a project’s Principal 
Investigator (PI), which is measured by HI index of the lead-person, would share 0.02% 
more of the funding share of a project in open pool of competitions (I, II, III, ABC) (90% 
confidence level) for each unit increase index in HI, other things being equal.  
International co-funding, on average, improves a project’s budget share by 0.2% (not 
statistically significant) more than a project which is only supported from domestic 
source, other things being equal.  
The host institution also has little effect. On average, the GC contribution to each project in 
the open competitions increases 0.09 for each additional index point (not significant). The 
project’s host institution of research capability index is measured by research funding per 
full-time faculty member (10000$). 
However, on average, an INTERGE3LS project is expected to have approximately 0.28% 
(95% confidence level) more than a project which is not, other things being equal.  
Moreover, for the coefficient for sector, on average, a health project is expected to have 
approximately 0.48% (99.9% confidence level) more than a project which is not, other 
things being equal.  
On average, each ON project is expected to have approximately 0.3% (90% confidence 
level) more share of GC contribution in the open fund pool of all Genome Canada contribution 
than a project which is not, other things being equal. This suggests that the peer reviewers 
appear to be more influenced by the location of the project than Genome Canada staff. 
Model C, contains the regional dummies and the sector dummies. The adj-R
2
 reaches a 
peak at 22%; more specified models with other contextual variables were tested but they 
offer little additional explanation power (based on the static adjusted R
2
). 
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Overall, this model suggests the processes in Competitions I, II, III and ABC delivered a 
weaker fit with the strategic of objectives of Genome Canada than the processes used by 
Genome Canada staff to develop the directed projects. This may be an artifact of the 
lessons learned from the earlier open competitions that were applied to the directed 
investments.  However, there is some possibility that there may have been cognitive 
biases operating in the open competitions, as the dummy for the Ontario region is 
positive and significant at 90% level, which should not be observed in a competition 
where research excellence is the goal rather than allocations based on past capacity.  
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6. Summary & Policy Implications 
 
6.1. Summary 
This study has added to the policy evaluation literature, offering specific insights into 
evaluation of Genome Canada. GC was established in April, 2000 to provide funding and 
information resources related to genomics research. GC research targets many key areas, 
such as health, agriculture, environment, forestry, fisheries, energy and mining.  
Since then, the scientific community has partnered with government, the private sector, 
and international organizations to fund research projects on genomics related subjects. 
Four open competitions (I, II, III and Applied Genomics in Bio-products and Crops or 
ABC), combined with a wide array of internally targeted and developed projects, have 
collectively been allocated more than C$2 billion in total investment for the 2000-2014 
period.  
This study assesses how well these research projects fit the stated goals of Genome 
Canada. The study assesses the fit between the goals and research investment decisions of 
GC. As a first step in this research, we conducted a review of Genome Canada operations 
to develop the background understanding of the system and its structure. After reviewing 
the goals, structure, selection processes and progress reports, we found that there was no 
explicit assessment of the fit between the stated goals and resource allocation decisions. 
This study targeted to fill this gap. 
Second, we investigated the methods used by GC to develop and implement their goals. 
Once we understood these methods, we developed a research approach to examine the fit 
between the goals and the outputs. We explored the resource allocation decisions of GC, 
especially, the individual projects from different sectors. An econometric model was built 
to test the allocations of funding for projects against the overall program stated objectives, 
namely to: develop and implement a coordinated strategy for the technology in Canada; 
bring together industry, governments, universities, research hospitals and the public to 
support large-scale genomics and proteomics research projects; provide accessibility to 
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science and technology platforms to researchers; and assist in attracting co-funding for 
projects from both domestic and international investors.  
Third, we determined that the review processes contain scientific, financial and 
management criteria. By using the STATA tool, we tested the relationship between the 
share of funds allocated to specific projects in the competitions and in the directed 
investments and the stated goals of the organization. The analysis revealed that the 
overall fit for the entire investment program between 2001 and 2011 was about 34%, 
which is quite strong. We found the most important variable affecting resource allocation 
was the quality of the principal investigator. Other stated goals of GC were either less 
important or insignificant. By segmenting the analysis into the open competition 
investments alone, we discovered the fit deteriorated (R
2
 dropped from 34% to 22%), 
which suggests the directed investments are a stronger fit with the goals. While we could 
not conclusively determine the cause, it might be attributed to (1) weaknesses in the peer-
review processes involving a large number of competitive projects, (2) greater 
competence in adjudication as the directed investments mostly followed the four open 
competitions, or (3) it could be due to particularly effective and strategic effort by 
Genome Canada staff. Further analysis would be needed to determine this.  
6.2. Conclusions 
First, the results of our study shows that about up to 35% of the variance in funding by 
project can be explained by goals of GC. This is actually quite good for this type of 
program. 
Second, the key variables that seemed to influence allocations were: health, ON, PI, 
competitions I, II, III, ABC, research, GE3LS, INTERGE3LS and International co-
founders. 
Third, somewhat surprisingly the fit for the open competitions was not as strong as for 
the entire portfolio. By inference, this means that the allocations directed by Genome 
Canada staff (i.e. not engaged in open competition) were generally more strategic (keep 
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in mind we cannot confirm in this study that their outputs and outcomes were any 
different—that would be a different type of analysis).  
This may be surprising to many, as there is a general view that bureaucrats are more 
susceptible to political interference than arms-length openly competitive processes. One 
of two factors could be contributing to this divergence. It is possible that the competitive 
process triggers cognitive gaps and biases among the peer-reviewers. There is some 
theory and evidence that peer review systems that are directed to assess multiple projects 
over a diverse set of variables will revert to system 1, fast and intuitive thinking that 
would lead to anchoring on a few operative factors and satisficing activity (Kahneman 
2002)
31
. Whether that is working here could be examined experimentally. The differential 
importance of sector and region for peer reviewers suggests something is going on here. 
Alternatively, it may be that the staffs of Genome Canada and the regional genome 
centers are as susceptible to incentives as many might hypothesize, but that their 
incentives drive them to proactively backfill and compensate for any gaps in the open 
competition results. It would be necessary to look at the incentive and operational 
mandates of the Genome Canada staff to determine what drives these behaviors. 
6.3. Limitations 
This study was done using publicly available data. Access to internal Genome Canada 
data—including the detailed proposals for the projects—would allow us to calibrate the 
model more precisely and, in a perfect world, determine if there are any learning by 
doing effects as the organization has matured.  
A second limitation is that we do not have any counterfactuals. The share of allocations 
was used as an in-sample differentiator. In a perfect world we would have full access to 
the structure and details of those proposals that failed to advance from LOI to full 
proposal and that were not funded. That would provide an all-in analysis of the efficacy 
and fit of the Genome decision system relative to its stated goals. 
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6.4. Extensions 
This study raises two interesting possibilities for further work. First, pending access to 
more detailed data on both successful and unsuccessful projects, it should be possible to 
more effectively refine the model and isolate the effect of key variables in decision 
making.  
This then could be used to assess the effect of framing and choice architecture in research 
decision making. As noted above, this analysis tends to provide empirical evidence in 
support of the possibility that peer-evaluation systems are cognitively limited in the 
context open competitions. We believe experimental work specifically related to the 
choices facing the peer-reviewers in Genome Canada could help more effectively 
develop appropriate choice architecture.  
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APPENDIXES 
Appendix I: PI kurtosis & codebook 
 
Figure 1 PI kurtosis 
 
Figure 2 PI codebook 
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Appendix II: Maclean Ranking 
Table 3 Maclean Ranking 
University 
Total Research Dollars  
($ per full-time faculty 
member) 
Total Research Dollars  
(10000$ per full-time faculty member) 
1. Toronto 350995  3.51  
2. Alberta 309332  3.09  
3. McMaster 308605  3.09  
4. McGill 268730  2.69  
5. Montréal 257238  2.57  
6. UBC 238875  2.39  
7. Queen's 216764  2.17  
8. Laval 211253  2.11  
9. Ottawa 194084  1.94  
10. Guelph 191884  1.92  
11. Manitoba 175400  1.75  
12. Western 171784  1.72  
13. Calgary 169787  1.70  
14. Waterloo 162683  1.63  
15. Victoria 158087  1.58  
16. Saskatchewan 156464  1.56  
17. Dalhousie 131691  1.32  
18. Carleton 101464  1.01  
19. Simon Fraser 99452  0.99  
20. UNBC 98700  0.99  
21. Sherbrooke 97811  0.98  
22. New Brunswick 91701  0.92  
23. Memorial 81761  0.82  
24. UPEI 71419  0.71  
25. Windsor 66923  0.67  
26. UQAM 65824  0.66  
27. Lakehead 64683  0.65  
28. UOIT 63601  0.64  
29. Trent 52902  0.53  
30. Regina 52893  0.53  
31. York 48195  0.48  
32. Lethbridge 47068  0.47  
33. Laurentian 46541  0.47  
34. St. Francis Xavier 45688  0.46  
35. Concordia 43483  0.43  
36. Cape Breton 40077  0.40  
37. Saint Mary's 35446  0.35  
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38. Moncton 30752  0.31  
39. Ryerson 30587  0.31  
40. Winnipeg 25743  0.26  
41. Acadia 25530  0.26  
43. Mount Allison 23956  0.24  
42. Mount Saint Vincent 24028  0.24  
44. Brock 23636  0.24  
45. Wilfrid Laurier 19620  0.20  
46. Brandon 14528  0.15  
47. Nipissing 14090  0.14  
48. Bishop's 9054  0.09  
49. St. Thomas 6941  0.07  
Source: http://tools.macleans.ca/ranking2008/selectindicators.aspx 
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Appendix III: Calculation of Frequency  
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Appendix IV: Table of Key Variables 
N=156 
 
PI research international INTERGE3LS health ON Directed 
0.67 3.51 0 0 0 1 0 
1.45 1.56 1 0 0 0 0 
16.11 2.51 0 1 1 1 1 
5.68 1.75 0 1 0 1 0 
3.79 1.72 0 1 0 0 0 
7.95 1.56 0 1 0 0 0 
13.73 2.69 0 1 0 0 0 
16.11 1.56 0 1 1 1 1 
0.64 0.92 0 0 0 0 0 
5.08 3.09 0 1 0 0 0 
5.15 2.39 0 1 0 0 0 
37.72 3.09 1 0 1 1 1 
5.15 2.39 1 0 0 0 1 
2.44 3.09 0 0 0 0 0 
3.76 2.33 0 1 1 0 1 
2.57 1.56 0 1 0 0 0 
12.25 3.51 0 1 0 1 0 
0.5 3.51 0 0 0 0 1 
10.94 1.94 0 0 0 0 1 
9.08 3.51 0 0 0 1 1 
1.26 1.75 0 0 0 1 1 
2.22 3.51 0 0 0 1 0 
5.68 3.51 1 0 0 0 1 
12 3.51 1 0 0 1 1 
5.49 2.17 1 0 0 0 0 
13.59 2.39 0 0 0 1 1 
0.25 3.51 1 0 0 1 0 
7.41 1.58 0 0 0 0 1 
25.13 1.92 0 0 0 1 1 
7.08 2.69 1 0 0 0 1 
6.62 1.7 0 1 0 0 0 
15.91 3.51 1 0 0 1 1 
5.38 2.57 0 0 0 0 1 
17.52 2.39 0 0 0 1 1 
24.08 2.39 0 1 0 0 0 
1.88 2.39 0 0 0 0 0 
11.54 2.57 0 1 0 0 1 
13.26 1.7 0 1 0 1 0 
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20.26 1.7 0 1 0 0 0 
25.13 1.92 0 0 0 1 1 
4.76 1.92 0 1 0 0 1 
25.13 1.92 1 0 0 1 1 
3 1.32 0 0 0 0 0 
15.57 1.75 0 1 0 0 0 
10.99 2.39 0 1 0 0 1 
25.13 1.92 0 1 0 0 0 
12.45 2.39 0 1 0 0 1 
1.39 0.43 1 0 0 0 0 
1.19 3.09 0 0 0 1 0 
26.11 2.39 0 0 0 1 1 
6.13 0.43 0 1 1 0 0 
3.91 0.99 0 0 0 0 0 
6 0.92 1 0 0 0 1 
2.64 2.39 0 1 0 0 0 
22 1.58 1 1 1 0 0 
1.94 2.11 1 1 0 0 0 
7.68 0.92  0 0 0 0 
6.15 2.74 0 1 0 0 1 
1.8 2.39 1 0 0 0 0 
7.89 2.74 0 1 1 0 0 
19.69 2.25 0 1 0 0 1 
10.18 2.39 0 0 0 0 1 
8 2.39 0 0 0 0 1 
2 2.57 0 0 0 0 0 
1.38 1.56 0 0 0 1 0 
11.39 2.39 0 1 0 0 0 
6.63 3.51 1 0 0 1 0 
6.94 1.69 0 0 0 0 0 
8.4 2.57 0 0 0 0 0 
3.43 1.7 0 0 0 0 0 
7.68 2.39 0 0 0 0 0 
1.33 3.09 0 0 0 0 0 
17.65 3.51 0 0 1 0 0 
7.76 2.57 0 0 0 0 0 
6.13 3.51 1 0 0 1 0 
5.14 2.39 0 0 0 0 0 
6.63 3.51 1 0 0 1 0 
8 3.51 1 0 1 1 1 
7.53 2.57 0 0 1 0 0 
10.95 3.51 1 0 1 1 0 
1.09 1.56 1 0 1 0 0 
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15.5 2.39 0 0 1 1 1 
19.57 2.69 0 0 1 0 0 
5.44 2.69 0 0 1 0 0 
1.78 2.39 1 0 1 0 0 
0.4 2.57 0 0 1 0 0 
15.22 2.39 1 0 1 0 1 
4.52 2.69 1 0 1 0 0 
12.69 3.51 0 0 1 1 0 
11.52 2.69 1 0 1 0 0 
1.58 2.39 0 1 1 0 0 
6.25 3.51 0 1 1 1 0 
53 3.51 1 0 1 1 1 
24 2.69 0 0 1 0 1 
9.1 2.39 0 0 1 0 0 
3.23 2.69 0 0 1 0 0 
24 2.69 0 0 1 0 1 
11.09 3.51 0 1 1 0 1 
24 2.69 1 0 1 0 1 
0.7 3.51 0 0 1 1 0 
0.25 1.94 0 0 1 0 1 
8.21 2.39 0 0 1 0 1 
5.36 2.69 1 0 1 0 1 
0.7 2.39 0 0 1 0 1 
19.24 3.51 0 0 0 0 1 
6.34 2.39 0 1 1 0 0 
0.5 0.99 1 0 1 0 0 
5.44 0.98 0 0 1 0 0 
4.17 1.72 0 0 0 0 1 
53 3.51 1 0 1 1 1 
0.6 1.75 0 1 1 1 0 
8.89 2.39 1 0 1 0 0 
5.19 2.69 0 0 1 0 0 
0.28 2.57 0 0 1 0 0 
1.32 2.11 0 0 1 0 1 
18.72 3.51 1 0 1 1 1 
2.58 2.39 1 1 1 0 0 
22.98 2.39 1 0 1 0 1 
5.36 2.69 0 0 1 0 0 
15.09 1.94 0 0 1 1 0 
13.57 3.51 0 0 0 0 1 
5.61 3.51 1 1 1 1 1 
0.2 3.51 0 0 1 1 0 
24.5 1.72 1 1 1 1 0 
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14.12 3.51 0 0 1 1 0 
14.19 3.09 1 0 1 1 1 
12.3 2.69 0 0 1 0 0 
7.35 3.51 0 0 1 1 0 
3.85 3.51 0 1 1 1 0 
4.9 2.39 0 0 1 0 0 
10.27 1.32 0 1 1 0 1 
2.5 2.57 0 0 1 0 0 
53 3.51 1 0 1 1 1 
10 1.94 0 0 1 1 1 
14.13 2.57 0 1 1 0 0 
5.08 3.51 0 0 1 1 0 
7.35 3.51 0 1 1 1 0 
5.13 2.57 0 0 1 0 0 
6.78 3.51 0 0 1 1 0 
13.59 2.39 0 1 0 0 0 
7.56 2.39 0 0 1 1 1 
1.45 2.39 1 1 1 0 0 
17.51 2.69 1 1 1 0 0 
5.08 3.3 0 1 1 1 0 
15.45 3.09 1 0 0 0 1 
23.16 2.57 0 1 1 0 0 
27.92 3.51 1 0 1 1 1 
12.6 2.39 1 1 1 0 1 
18.31 3.51 0 1 1 0 0 
10 1.94 0 0 1 1 1 
1.09 2.39 1 1 1 0 0 
8.97 2.69 0 0 1 0 0 
0.82 2.39 0 0 1 1 1 
19.04 2.39 0 1 1 0 1 
5.09 3.51 1 0 1 1 0 
5.24 2.39 1 0 1 0 0 
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Appendix V: Original STATA DATA 
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Appendix VI: Comparisons of PI and Log PI 
 
 
 
Figure 4 Comparisons of PI and Log PI 
 
 
 
Figure 5 Comparison of regression on PI and Log PI 
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Appendix VII: Regression Table 
Y1: GC-TOTAL 
 
Model A 
 
 
Model B and Model C 
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Model D 
 
 
 
 
Y2: OPEN-Competition 
 
Model A: 
 
 
  
 68 
 
Model B: 
 
 
 
Model C: 
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Appendix VIII: Genome Canada Database 
The detailed database about dummy variables is founded by STATA as follows: 
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Appendix IX: STATA Summary Table 
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